Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roman Gulati

Showing results (131-140 of 154) with videos related to

Pageof 16
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 16, 2025
Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate CancerSean R Miller, Dana H Chung, Rachel T Gonzalez, et al.
Radiology|March 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, et al.
Clinical Genitourinary Cancer|September 20, 2017
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract TumorsJorge D Ramos, Jonathan T Wingate, Roman Gulati, et al.
European Urology|December 4, 2021
A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks AnalysisSarah P Psutka, Roman Gulati, Michael A S Jewett, et al.
Prostate Cancer and Prostatic Diseases|December 23, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Todd Yezefski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2017
Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate CancerElahe A Mostaghel, Eunpi Cho, Ailin Zhang, et al.
The Prostate|September 13, 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsAlexandra O Sokolova, Catherine H Marshall, Rebeca Lozano, et al.
Annals of Internal Medicine|July 16, 2014
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefitsIris Lansdorp-Vogelaar, Roman Gulati, Angela B Mariotto, et al.
The Prostate|March 23, 2021
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancerLaura S Graham, Lawrence D True, Roman Gulati, et al.
European Urology Oncology|February 7, 2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after <sup>177</sup>Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair GenesRuben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, et al.
Pageof 16

Showing results (131-140 of 154) with videos related to

Sort By:
Pageof 16
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 16, 2025
Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate CancerSean R Miller, Dana H Chung, Rachel T Gonzalez, et al.
Radiology|March 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, et al.
Clinical Genitourinary Cancer|September 20, 2017
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract TumorsJorge D Ramos, Jonathan T Wingate, Roman Gulati, et al.
European Urology|December 4, 2021
A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks AnalysisSarah P Psutka, Roman Gulati, Michael A S Jewett, et al.
Prostate Cancer and Prostatic Diseases|December 23, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Todd Yezefski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2017
Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate CancerElahe A Mostaghel, Eunpi Cho, Ailin Zhang, et al.
The Prostate|September 13, 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsAlexandra O Sokolova, Catherine H Marshall, Rebeca Lozano, et al.
Annals of Internal Medicine|July 16, 2014
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefitsIris Lansdorp-Vogelaar, Roman Gulati, Angela B Mariotto, et al.
The Prostate|March 23, 2021
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancerLaura S Graham, Lawrence D True, Roman Gulati, et al.
European Urology Oncology|February 7, 2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after <sup>177</sup>Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair GenesRuben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, et al.
Pageof 16